Mumbai: Kilitch Drugs Limited (BSE: 524500 | NSE: KILITCH), a prominent player in the pharmaceutical manufacturing sector, has posted strong quarterly results for Q4FY25, reporting a 212% year-on-year growth in Standalone Profit After Tax (PAT) and a 44% increase in revenue from operations, driven by robust demand and international market expansion.
The company’s unaudited financial results for the quarter ended March 31, 2025, reflect significant momentum:
Q4FY25 Standalone Highlights:
- PAT: ₹1,137.41 lakh, up 212% YoY
- Revenue from Operations: ₹18,158.73 lakh, up 44% YoY
Q4FY25 Consolidated Highlights:
- Consolidated PAT: ₹1,021.86 lakh, up 178% YoY
- Consolidated Revenue: ₹6,122.58 lakh, up 37% YoY
FY25 Annual Standalone Performance:
- Net Profit: ₹3,115.69 lakh, a 77% increase from ₹1,757.38 lakh in FY24
- Revenue from Operations: ₹18,158.73 lakh, up 38% from ₹13,159.90 lakh in FY24
“We are proud to report another quarter of significant growth. Our 212% PAT growth and 44% revenue increase reflect the strength of our operations and sustained demand across markets,” said Mukund Mehta, Managing Director, Kilitch Drugs. “We remain committed to driving sustainable performance and long-term value for our stakeholders.”
Kilitch Drugs: Focus on Innovation
Kilitch Drugs continues to scale its operations in both domestic and international markets, offering a wide range of pharmaceutical products, including injectables, parenterals, oral solids, and effervescent formulations.
The company’s consistent performance underscores its strategic focus on innovation, quality manufacturing, and expanding global footprints.
